Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVID-19: randomized open-label adaptive proof-of-concept trial of itraconazole
2020-001243-15Phase 2Terminated
- Sponsor
- UZ Leuven
- Start
- Mar 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Itraconazole plus standard of care with Standard of care control (2 arms). Primary endpoint: Clinical status at day 15. Started Mar 2020; status: terminated.
02
Drugs
itraconazole
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001243-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001243-15.